6 completed, 4 active not recruiting, 4 recruiting. 9 Phase 2, 8 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 4, Active not recruiting 3, Completed 2 |
| Phase 1 | 8 | Completed 6, Recruiting 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow quemliclustat: new trials by email Literature Review of quemliclustat trials Research Report on quemliclustat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer Quemliclustat, Biospecimen Collection, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 27 | 2026-10-20 | 2026-10-22 |
| Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) Quemliclustat - Healthy Participants | Phase 1 | Completed | Arcus Biosciences, Inc. | 8 | 2026-02-03 | 2026-05-01 |
| Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Quemliclustat, Placebo, Nab-paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Active not recruiting | Arcus Biosciences, Inc. | 610 | 2024-12-13 | 2026-09-29 |
| Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat - Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Gulam Manji | 60 | 2024-05-10 | 2026-02-27 |
| Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) Gemcitabine, Cisplatin, Zimberelimab - Biliary Tract Carcinoma, Cholangiocarcinoma | Phase 2 | Active not recruiting | Nataliya Uboha | 33 | 2024-03-08 | 2026-08-17 |
| Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer Quemliclustat, Etrumadenant, Zimberelimab - Oligometastatic Prostate Cancer | Phase 2 | Recruiting | Catherine Spina | 23 | 2023-07-01 | 2025-05-20 |
| Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Biospecimen Collection, Computed Tomography, Core Biopsy - Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 56 | 2023-03-07 | 2026-05-22 |
| Study With Various Immunotherapy Treatments in Participants With Lung Cancer Domvanalimab, Quemliclustat, Zimberelimab - Advanced Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | Gilead Sciences | 400 | 2023-02-21 | 2026-06-01 |
| A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies Domvanalimab, Quemliclustat, Zimberelimab - Gastrointestinal Tract Malignancies | Phase 2 | Active not recruiting | Arcus Biosciences, Inc. | 332 | 2022-06-10 | 2026-09-29 |
| An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. AB680, Etrumadenant, Zimberelimab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Arcus Biosciences, Inc. | 227 | 2021-05-10 | 2025-10-20 |
| A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers AB680, Placebo - Healthy Volunteers | Phase 1 | Completed | Arcus Biosciences, Inc. | 32 | 2020-10-20 | 2024-05-24 |
| Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer Etrumadenant, Zimberelimab, Quemliclustat - Prostatic Neoplasms, Castration-Resistant, Androgen-Resistant Prostatic Neoplasms | Phase 1 / Phase 2 | Completed | Arcus Biosciences, Inc. | 173 | 2020-07-07 | 2025-07-22 |
| A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies AB680, Zimberelimab, Nab-paclitaxel - Advanced Pancreatic Cancer | Phase 1 | Completed | Arcus Biosciences, Inc. | 196 | 2019-11-06 | 2026-09-09 |
| A Study to Investigate the Safety of AB680 in Healthy Volunteers AB680, Placebo - Healthy Volunteers | Phase 1 | Completed | Arcus Biosciences, Inc. | 64 | 2018-10-16 | 2024-05-24 |
Pancreatic Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Bile Duct Neoplasms (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Prostatic Neoplasms, Castration-Resistant (1) · Stomach Neoplasms (1) · Ureteral Neoplasms (1) · Urinary Bladder Neoplasms (1)
Arcus Biosciences, Inc. (8) · Catherine Spina (1) · Fred Hutchinson Cancer Center (1) · Gilead Sciences (1) · Gulam Manji (1) · Jonsson Comprehensive Cancer Center (1) · Nataliya Uboha (1)
United States (12) · Australia (4) · France (4) · South Korea (4) · Canada (3) · Italy (3) · Spain (3) · United Kingdom (3) · Austria (1) · Belgium (1) · Chile (1) · Czechia (1) · Georgia (1) · Germany (1) · Japan (1)
Catherine S. Spina, MD, PhD (1) · Gulam Manji, MD, PhD (1) · Nataliya Uboha, MD, PhD (1) · Rosa Nadal Rios, MD, PhD (1) · Zev A Wainberg (1)